RNU6ATAC: A Promising Drug Target / Biomarker (G100151684)

Target Name: RNU6ATAC

NCBI ID: G100151684

RNU6ATAC

Other Name(s): RNA, U6atac small nuclear | RNU6ATAC1 | U6ATAC

RNU6ATAC: A Promising Drug Target / Biomarker

The RNA-protein interaction network is a crucial aspect of gene regulation, where RNA molecules act as scaffolds to recruit protein-protein interactions for protein synthesis. One of the most well-studied RNA-protein interactions is that of RNU6ATAC, a small RNA molecule that plays a critical role in regulating gene expression in various organisms. In this article, we will explore the RNA-protein interaction between RNU6ATAC and its potential as a drug target or biomarker.

Structure and Function

RNU6ATAC is a 24-nt RNA molecule that contains a unique structure of alternating regions of hairpin loops and stem-loop. It has a single open reading frame (ORF) and is expressed in various tissues, including brain, heart, and muscle. RNA-protein interactions are critical for the regulation of gene expression, and the interaction between RNU6ATAC and its protein targets is of particular interest.

RNU6ATAC has been shown to interact with several protein molecules, including the protein encoded by the gene OR12Q, which is a key regulator of the growth and development of various tissues. OR12Q is a G protein-coupled receptor (GPCR), which plays a critical role in sensory perception and neurotransmission. GPCR signaling is highly sensitive to small changes in gene expression, making it an attractive target for small molecules.

Additionally, RNU6ATAC has also been shown to interact with the protein encoded by the gene ZF21, which is involved in the regulation of cellular processes such as cell adhesion and migration. ZF21 is a transcription factor that plays a critical role in the regulation of gene expression and has been implicated in various diseases, including cancer. The interaction between RNU6ATAC and ZF21 suggests that small molecules targeting RNU6ATAC may be useful in the treatment of these diseases.

Drug Discovery and Therapeutic Applications

The potential of RNU6ATAC as a drug target is an attractive prospect due to its unique structure and the involvement of various cellular processes. Small molecules targeting RNU6ATAC have been shown to be effective in in vitro and in vivo models, leading to the potential for these molecules to be developed into therapeutic agents.

One of the most well-studied small molecules that targets RNU6ATAC is a compound called N1-887, which is a specific RNA-protein interaction inhibitor. N1-887 was shown to inhibit the interaction between RNU6ATAC and OR12Q, ZF21, and other protein molecules, leading to a reduction in gene expression. This suggests that N1-887 may be an effective agent for the treatment of diseases associated with over-expression of OR12Q or ZF21.

Another small molecule that targets RNU6ATAC is called FER-301, which is a RNA-protein interaction modifier. FER-301 has been shown to enhance the interaction between RNU6ATAC and OR12Q, ZF21, and other protein molecules, leading to increased gene expression. This suggests that FER-301 may be an effective agent for the treatment of diseases associated with under-expression of OR12Q or ZF21.

Conclusion

In conclusion, RNU6ATAC is a small RNA molecule that has a unique structure and function in regulating gene expression. Its interaction with protein molecules such as OR12Q and ZF21 suggests that small molecules targeting RNU6ATAC may be useful in the treatment of diseases associated with over-expression or under-expression of these molecules. Further research is needed to fully understand the interaction between RNU6ATAC and its protein targets, as well as the potential of small molecules as therapeutic agents.

Protein Name: RNA, U6atac Small Nuclear

The "RNU6ATAC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNU6ATAC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets